Trial results
$BIOA — BGE-102
BioAge Labs, Inc. (BIOA) BGE-102: trial results in Obesity with baseline inflammation at elevated cardiovascular risk, 2026.
The catalyst
"We anticipate reporting topline data from QUELL-CV in the fourth quarter of 2026."
— BioAge Labs, Inc., 10-Q filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
BIOA-BGE102-2026- Company
- BioAge Labs, Inc.
- Kind
- Trial results
- Indication
- Obesity with baseline inflammation at elevated cardiovascular risk
- Window
- 2026-01-01 – 2026-12-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.